Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16144539 | 0.85 | MAOB (0.42) | NFE2L2ACHEMAOBSLC6A4SLC6A2 | |
| SCHEMBL260934 | 0.84 | KIF11 (0.47) | ACHEKIF11MAOBHPGDPPARG | |
| SCHEMBL254534 | 0.80 | GPR3 (0.50) | NFE2L2KIF11 | |
| SCHEMBL29435934 | 0.80 | GPR3 (0.50) | NFE2L2KIF11 | |
| SCHEMBL17501722 | 0.79 | MAOB (0.38) | NFE2L2ACHEMAOBSLC6A4SLC6A2 | |
| SCHEMBL9163039 | 0.79 | NFE2L2 (0.41) | NFE2L2ACHEMAOBESR1ESR2 | |
| SCHEMBL7940650 | 0.78 | NFE2L2 (0.39) | NFE2L2ACHEMAOBSLC6A4SLC6A2 | |
| SCHEMBL246293 | 0.78 | MAOB (0.40) | NFE2L2ACHEMAOBSLC6A4SLC6A2 | |
| SCHEMBL6764359 | 0.78 | KCNH2 (0.44) | KIF11NPC1RAB9A | |
| SCHEMBL27695264 | 0.78 | KIF11 (0.41) | ACHEKIF11HPGDPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194917-A1 | BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-06-23 | — | — | US | disclosed |
| US-20220048915-A1 | Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2022-02-17 | — | — | US | disclosed |
| US-11248000-B2 | Quinazoline and indole compounds to treat medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210371420-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2021-12-02 | — | — | US | disclosed |
| US-20210353606-A1 | PqsR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2021-11-18 | — | — | US | disclosed |
| US-11040973-B2 | Inhibitors of kinase networks and uses thereof | PURDUE RESEARCH FOUNDATION | 2021-06-22 | — | — | US | disclosed |
| US-10981887-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10961252-B2 | Quinazoline and indole compounds to treat medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10793514-B2 | Glutamine transport inhibitors and methods for treating cancer | VANDERBILT UNIVERSITY (US) | 2020-10-06 | — | — | US | disclosed |
| US-20200308173-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2020-10-01 | — | — | US | disclosed |
| US-7910616-B2 | Proteasome inhibitors | NEREUS PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20100331348-A1 | TROPANE DERIVATIVES USEFUL AS PESTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331348-A1 | TROPANE DERIVATIVES USEFUL AS PESTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090298906-A1 | PROTEASOME INHIBITORS | NEREUS PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-7511063-B2 | High affinity quinoline-based kinase ligands | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7485641-B2 | Substituted 3-amino-pyrrolidino-4-lactams | PFIZER, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | SCHERING CORPORATION | 2008-02-21 | — | — | US | disclosed |
| US-20070299076-A1 | Substituted 3-Amino-Pyrrolidino-4-Lactams | PFIZER INC | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981887-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | NFE2L2 288/4885ACHE 4195/4885KIF11 3622/4885 |
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | IRAK1, IRAK2, IRAK3 | NFE2L2 2327/4885ACHE 4774/4885KIF11 3901/4885 |
| US-11248000-B2 | Quinazoline and indole compounds to treat medical disorders | CFB, TFPI, MAOB | NFE2L2 734/4885ACHE 347/4885KIF11 4000/4885 |
| US-20220194917-A1 | BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR COMPOUNDS | ESR1, ESR2, GPER1 | NFE2L2 83/4885ACHE 4788/4885KIF11 4172/4885 |
| US-20200308173-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | KDM1B, JMJD6, KDM1A | NFE2L2 2183/4885ACHE 2054/4885KIF11 2865/4885 |
| US-10961252-B2 | Quinazoline and indole compounds to treat medical disorders | CFB, TFPI, MAOB | NFE2L2 734/4885ACHE 347/4885KIF11 4000/4885 |
| US-11040973-B2 | Inhibitors of kinase networks and uses thereof | KDM1B, JMJD6, KDM1A | NFE2L2 2183/4885ACHE 2054/4885KIF11 2865/4885 |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | CDKL2, CDK2, CDKL1 | NFE2L2 1540/4885ACHE 4025/4885KIF11 881/4885 |
| US-20210371420-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | KDM1B, JMJD6, KDM1A | NFE2L2 2183/4885ACHE 2054/4885KIF11 2865/4885 |
| US-10793514-B2 | Glutamine transport inhibitors and methods for treating cancer | SLC1A5, SLC7A11, SLC3A2 | NFE2L2 202/4885ACHE 4822/4885KIF11 2270/4885 |
| US-20070299076-A1 | Substituted 3-Amino-Pyrrolidino-4-Lactams | PRMT1, PRMT7, PRMT3 | NFE2L2 4475/4885ACHE 2607/4885KIF11 2963/4885 |
| US-20220048915-A1 | Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof | MAPK11, WEE1, NOS1 | NFE2L2 1168/4885ACHE 2625/4885KIF11 1867/4885 |
| US-20100331348-A1 | TROPANE DERIVATIVES USEFUL AS PESTICIDES | DDT, ACHE, TPM3 | NFE2L2 3091/4885ACHE 2/4885KIF11 4025/4885 |
| US-20090298906-A1 | PROTEASOME INHIBITORS | PSMB1, PSME1, PSME3 | NFE2L2 365/4885ACHE 4104/4885KIF11 3427/4885 |
| US-20210353606-A1 | PqsR INVERSE AGONISTS | QRFPR, P2RY11, QARS1 | NFE2L2 1310/4885ACHE 2369/4885KIF11 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.